RT Journal Article
T1 Drug-Loaded Hydrogels for Intraocular Lenses with Prophylactic Action against Pseudophakic Cystoid Macular Edema
A1 Toffoletto, Nadia
A1 Salema-Oom, Madalena
A1 Anguiano Igea, Soledad
A1 Álvarez Lorenzo, Carmen
A1 Saramago, Benilde
A1 Serro, Ana Paula
K1 Therapeutic ophthalmic lenses
K1 Posterior segment diseases
K1 Drug release
K1 Anti-inflammatory drug
K1 Molecular imprinting
K1 Functionalized hydrogels
AB Pseudophakic cystoid macular edema (PCME), caused by chronic inflammation, is the most common cause of visual impairment in the medium-term after cataract surgery. Therefore, the prophylactic topical administration of combined steroidal and non-steroidal anti-inflammatory drugs is commonly done. Drug-eluting intraocular lenses (IOLs) gained interest as an efficient way to overcome the compliance issues related to the use of ocular drops without the need for additional surgical steps. The incorporation of functional monomers and molecular imprinting were herein applied to design hydrogels suitable as IOLs and able to co-deliver steroidal (dexamethasone sodium phosphate) and non-steroidal (bromfenac sodium) drugs. The incorporation of N-(2-aminopropyl) methacrylamide (APMA) increased the drug uptake and improved the in vitro release kinetics. Imprinting with bromfenac resulted in a decreased drug release due to permanent drug bonding, while imprinting with dexamethasone increased the amount of dexamethasone released after dual-drug loading. The application of a mathematical model to predict the in vivo drug release behavior suggests the feasibility of achieving therapeutic drug concentrations of bromfenac and dexamethasone in the aqueous humor for about 2 and 8 weeks, respectively, which is compatible with the current topical prophylaxis after cataract surgery
PB MDPI
YR 2021
FD 2021
LK http://hdl.handle.net/10347/26669
UL http://hdl.handle.net/10347/26669
LA eng
NO Pharmaceutics 2021, 13(7), 976; https://doi.org/10.3390/pharmaceutics13070976
NO This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement N° 813440 (OR-BITAL—Ocular Research by Integrated Training and Learning) and is also supported by Fundação para a Ciência e Tecnologia (FCT) [UID/QUI/00100/2019, UIDB/00100/2020, and UID/BIM/04585/2020].
DS Minerva
RD 29 abr 2026